Tirzepatide Dosage Calculator, Protocols, and Dosage Chart
How do you dose tirzepatide for weight loss, microdosing, or maintenance?
Tirzepatide (Mounjaro / Zepbound) Dosing: Clinical Trial Data & Pharmacokinetics
Tirzepatide dosing has three different floors that are easy to collapse into one. The labeled starter dose is 2.5 mg weekly, held for at least four weeks so the gastrointestinal system can adapt. The lowest long-duration obesity-trial dose is 5 mg weekly, which produced -15.0% body-weight change at 72 weeks in non-diabetic obesity.¹ The lowest measured human dose in a registered trial is 1 mg weekly, from an earlier type 2 diabetes dose-ranging study.¹³
Those floors answer different questions. The 2.5 mg floor answers, "Where does the label start?" The 5 mg floor answers, "Where does long-duration obesity evidence begin?" The 1 mg floor answers, "How low has human pharmacologic activity been directly measured?" A good dosing page should keep those questions separate.
Tirzepatide sends two weekly gut-hormone signals. The lower-dose personality is GIP-forward; as dose rises, the GLP-1 arm becomes more visible for appetite suppression, stomach-emptying delay, nausea, and heart-rate signal.⁸ It has no meaningful glucagon arm, so it should not be read like retatrutide.
The useful frame is sustained signal, not receptor maximalism. A 2.5 mg dose can sit inside the native post-meal GLP-1 signal range while still carrying a stronger relative GIP signal. A 5 mg dose reaches the first long-duration obesity-trial anchor. Above that, the question becomes whether extra appetite, waist, glucose, or liver-fat benefit is worth the higher side-effect load.
| Dose question | Best local answer | Evidence boundary |
|---|---|---|
| Label starter | 2.5 mg weekly for at least 4 weeks | Starter dose, not the long-duration obesity-trial floor |
| First obesity-trial dose | 5 mg weekly | 72-week non-diabetic obesity arm¹ |
| Stop-short active dose | 10 mg weekly | Captures about 93% of the 15 mg mean weight-loss result¹ |
| Trial ceiling | 15 mg weekly | Do not exceed the labeled and trial-tested ceiling |
| Microdose band | 0.5-2 mg weekly | Translation from 1 mg T2D trial activity, PK, and mechanism; not 72-week obesity proof¹³ |
| Low-dose floor | 2.5 mg weekly | Label starter plus short dose-isolated non-diabetic data¹⁴ |
| Maintenance band | 5-10 mg weekly, with 2.5 mg as a lower-dose track | Continuation evidence is strong; step-down evidence is mixed direct, design-level, and real-world⁹ ¹² ¹⁴ |
| Titration guardrail | Minimum 4-week holds | Steady state, gastric-emptying adaptation, heart-rate response, and oral-contraceptive interaction all cluster around dose changes |
Tirzepatide Clinical Results
The obesity dose-response is strong but flattens above 10 mg. In the 72-week non-diabetic obesity trial, 5 mg, 10 mg, and 15 mg all produced large weight loss, but the gain from 10 mg to 15 mg was small compared with the step from placebo to 5 mg.¹ That is the core reason many users stop short of the ceiling once appetite, waist, glucose, and side effects are controlled.
| Population / endpoint | Dose | Result |
|---|---|---|
| Non-diabetic obesity, 72 weeks | 5 mg | -15.0% body-weight change¹ |
| Non-diabetic obesity, 72 weeks | 10 mg | -19.5% body-weight change¹ |
| Non-diabetic obesity, 72 weeks | 15 mg | -20.9% body-weight change¹ |
| Direct head-to-head obesity trial | Up to 15 mg tirzepatide vs 2.4 mg semaglutide | -20.2% vs -13.7% at 72 weeks² |
| Non-diabetic obesity, DXA substudy | Pooled 5/10/15 mg | About 75:25 fat-to-lean loss ratio³ |
| Type 2 diabetes, body-composition imaging | Therapeutic range | More mixed and instrument-specific than the non-diabetic DXA result⁴ |
| Type 2 diabetes with fatty liver, MRI substudy | 15 mg | Large liver-fat reduction in a T2D MRI population⁶ |
| Biopsy-confirmed MASH with fibrosis | 15 mg | 62% MASH resolution vs 10% placebo¹⁰ |
The body-composition result should stay attached to its evidence source. The non-diabetic tirzepatide DXA substudy is favorable, about 75:25 fat-to-lean loss.³ The semaglutide obesity-trial DXA split is closer to 62:38. That comparison supports tirzepatide as the stronger body-composition choice, but it is cross-trial evidence, not a head-to-head maintenance-dose DXA trial.
Type 2 diabetes is a different lens. GIP signaling is often impaired in T2D, so the same nominal tirzepatide dose may not produce the same body-composition profile as it does in non-diabetic obesity. The T2D imaging data are useful, but they should not be used to flatten every population into one clean ratio.⁴
Body size also changes the practical feel of a dose. Lower body weight generally means higher exposure at the same milligram dose, while very high body weight can dilute exposure. Low albumin can matter too, because tirzepatide is highly albumin-bound; total drug exposure can look ordinary while the free fraction feels less ordinary. The dose still comes from response and tolerability, not body weight alone.
Tirzepatide Dosage Chart
The best dose is the lowest dose that keeps the right markers moving with acceptable side effects. For active weight loss, those markers are appetite, weight trend, waist, glucose, blood pressure, and tolerability. For maintenance, the markers change: weight stability, waist stability, hunger, strength, protein adherence, and labs matter more than continued loss.
| Band | Weekly dose | What it means | Evidence quality |
|---|---|---|---|
| Microdose | 0.5-2 mg | Sub-label low-dose use for metabolic or maintenance translation | Human 1 mg T2D anchor plus PK/mechanism extrapolation¹³ |
| Low-dose floor | 2.5 mg | Label starter; plausible low-dose maintenance floor | Label starter plus 4-week dose-isolated non-diabetic cohort¹⁴ |
| First therapeutic obesity dose | 5 mg | Lowest 72-week non-diabetic obesity-trial dose | Strong obesity RCT evidence¹ |
| Stop-short active dose | 7.5-10 mg | Common active-loss or maintenance range when 5 mg is insufficient | Dose-response plus RWE support¹ ¹² |
| High dose | 12.5-15 mg | Ceiling range when response, baseline risk, or T2D resistance requires it | Strong RCT ceiling; higher GI burden¹ |
Before starting, establish a baseline. Weight is useful, but it is not enough. Track waist, blood pressure, fasting glucose, fasting insulin if available, HbA1c, lipids, liver enzymes, resting heart rate, and body composition if DXA or a consistent BIA device is accessible. During therapy, the most useful signals are trend-based: appetite returning too early, waist moving before weight, strength dropping despite protein, or resting heart rate rising meaningfully from baseline.
Mounjaro and Zepbound Dose Schedule
The labeled tirzepatide ladder moves in 2.5 mg steps every four weeks. Holding longer is common when nausea, constipation, fatigue, rising resting heart rate, or appetite control is already acceptable. Escalating faster than the label is where many avoidable side effects start.
| Weeks | Dose | Practical read |
|---|---|---|
| 1-4 | 2.5 mg weekly | Starter and tolerance dose; now also has short dose-isolated low-dose evidence¹⁴ |
| 5-8 | 5 mg weekly | First long-duration obesity-trial dose¹ |
| 9-12 | 7.5 mg weekly | Intermediate step when 5 mg is not enough |
| 13-16 | 10 mg weekly | Captures most of the 15 mg mean result with less top-dose burden¹ |
| 17-20 | 12.5 mg weekly | Bridge to ceiling when the response requires it |
| 21+ | 15 mg weekly | Trial and label ceiling |
Tirzepatide has a roughly 5-day half-life. Concentration rises across the first several weekly doses and is close to steady state after about four weeks.⁷ That is why the four-week hold matters: the complete effect of a dose change is not visible in the first few days.
That same window matters for oral contraceptives. Tirzepatide can reduce oral contraceptive exposure after initiation and after dose escalation because gastric emptying slows. Label guidance is to use a non-oral method or add barrier contraception for 4 weeks after starting and for 4 weeks after each dose increase.
Microdosing Tirzepatide
A tirzepatide microdose is best defined as below 2.5 mg weekly. The practical band is usually 0.5, 1.0, 1.5, or 2.0 mg weekly. The 2.5 mg dose is better described as the low-dose starter or maintenance floor, because it is the labeled starting dose and now has short direct non-diabetic data.¹⁴
The microdose use case is not rapid obesity-trial weight loss. It is lower-dose tolerability testing, metabolic-marker support, cautious step-down after a therapeutic course, or maintenance translation when a user is already stable. At 1-2 mg weekly, the evidence is a chain: direct 1 mg human activity in T2D, linear pharmacokinetics across the dose range, and mechanism.¹³ That chain is useful, but it is not the same as a 72-week obesity trial.
| Dose | Evidence anchor | What can be said |
|---|---|---|
| 0.5 mg weekly | Extrapolated | Plausible low-signal experiment; not a measured obesity outcome |
| 1.0 mg weekly | Direct 26-week T2D dose-ranging arm¹³ | Human pharmacologic activity exists; endpoint was glycemic, not long-term obesity |
| 1.5-2.0 mg weekly | Interpolation from 1 mg and 2.5 mg anchors | Plausible metabolic/maintenance band; outcome estimates are projections |
| 2.5 mg weekly | Label starter plus Barrea 2026 short cohort¹⁴ | Direct short non-diabetic signal; still not long-duration maintenance RCT proof |
Tirzepatide sends a stronger GIP signal than GLP-1 signal.⁸ In fat tissue, GIP-receptor biology may increase energy wasting through a calcium-pump cycle.⁷ That mechanism supports the low-dose hypothesis, but it does not prove that every microdose preserves the full therapeutic-dose body-composition result.
For vial-based microdosing, concentration matters more than vial size alone. A 10 mg vial mixed with 2 mL BAC water gives 5 mg/mL. A 1 mg dose draws 0.2 mL, or 20 units on a U-100 syringe. A 0.5 mg split draws 0.1 mL, or 10 units. Smaller draws demand steadier technique and more attention to concentration.
Tirzepatide Maintenance Dose After Weight Loss
For many maintainers, the practical dose is 5-10 mg weekly. That band is anchored by the 72-week non-diabetic obesity dose-response curve and by real-world prescribing patterns.¹ ¹² The lower-dose track is 2.5 mg weekly, especially after weight has been stable for months and the user wants less drug exposure. That lower track has a short dose-isolated signal and real-world support, but it is not long-duration maintenance RCT proof.¹² ¹⁴
The strongest maintenance evidence is continuation versus stopping. In the withdrawal trial, people who continued tirzepatide maintained their loss far better than those switched to placebo: 89.5% of continuators held at least 80% of their loss, while the placebo-switch group regained weight.⁹ The trial proves that continuing therapy matters. It does not prove every step-down schedule.
The direct step-down trial is testing 5 mg step-down against continued maximum-tolerated dosing. Results have not published; until they do, the trial is design-level evidence only.⁹ That boundary matters: 5 mg maintenance is plausible and well anchored; it is not the same as published head-to-head step-down results.
| Maintenance path | Dose | Evidence read | Good fit |
|---|---|---|---|
| Continue effective dose | 10-15 mg weekly | Direct continuation evidence from the withdrawal trial⁹ | Still losing, still obese-range, or hunger returns quickly |
| Step down | 7.5-10 mg weekly | Dose-response plus practice | Goal achieved, but 5 mg feels too light |
| Standard maintenance | 5 mg weekly | Obesity-trial floor plus step-down trial design | Stable appetite, waist, and labs |
| Lower-dose maintenance | 2.5 mg weekly | Short dose-isolated data plus RWE | Stable maintainer with strong food/training base |
| Schedule extension | 2.5-5 mg every 10-14 days | Community practice | Evidence-light; watch hunger in the back half of the interval |
Step down slowly: 15 -> 10 -> 7.5 -> 5 mg, holding each step for 8-12 weeks before deciding whether to reduce again. If hunger rises within 72 hours of injection, waist drifts, weight climbs more than about 2 lb per month, resting heart rate stays elevated, or strength drops despite protein and training, the lower dose is not carrying the load cleanly.
Split Dosing and Frequency
The clinical schedule is once weekly. Splitting the same weekly total into two injections, often every 3-4 days, is a tolerability strategy used outside the formal trial schedule. A smaller per-injection peak may reduce nausea and heart-rate pressure during escalation; a smaller trough may reduce the day 5-6 hunger return some users report. The evidence is pharmacokinetic and practice-based, not controlled outcome evidence.
| Pattern | Example | Evidence boundary |
|---|---|---|
| Weekly | 5 mg every 7 days | Trial and label schedule |
| Twice weekly | 2.5 mg every 3.5 days for a 5 mg weekly total | PK/practice strategy for peaks and troughs |
| Every 3 days | About 43% of the weekly total per injection | More frequent than label; mainly a smoothing strategy |
| Every 10-14 days | 2.5-5 mg extended interval | Community maintenance practice; no controlled tirzepatide trial coverage |
Schedule extension is the weakest evidence layer. With a roughly 5-day half-life, a biweekly schedule creates a real valley before the next injection. If hunger, waist, or weight drift appears in the back half of the interval, weekly dosing is the cleaner maintenance schedule.
Compounded Tirzepatide Dosage
Branded Mounjaro and Zepbound pens are fixed-dose products. A 5 mg pen delivers 5 mg. It does not create a 1 mg microdose, a 2 mg split, or a custom intermediate step. Vial-based dosing is where concentration and syringe-unit math matter.
Product access and compounding rules change. Do not assume a specific product format is currently legal, available, or clinically appropriate. If vial-based tirzepatide is being used under clinician supervision, verify the source, concentration, sterility expectations, and current rules before doing dose math. The calculator only answers the arithmetic question: how many milliliters and U-100 units correspond to a target milligram dose.
The core formula is:
Volume to draw (mL) = desired dose (mg) ÷ concentration (mg/mL)
Concentration comes from the vial and BAC water:
Concentration (mg/mL) = total vial amount (mg) ÷ BAC water added (mL)
The vial-size choice, the per-vial BAC water and syringe-unit charts for the 10, 15, 20, 30, and 60 mg vials, and the full mixing walkthrough live on the GLP-1 reconstitution calculator. The total milligrams in the vial are fixed; BAC water only changes concentration and draw volume.
How FoxAI Calculates Your Tirzepatide Dose
The FoxAI calculator uses vial size, BAC water volume, weekly target dose, and frequency to return concentration, draw volume, and U-100 syringe units. It handles label doses, lower-dose maintenance, microdose values, and split schedules. The calculation is arithmetic. The dose decision needs context the calculator cannot supply: population, phenotype, dose history, resting heart rate, oral medication timing, and what the markers are doing.
FAQ
Dosing basics
What is the starting dose of tirzepatide?
The labeled starting dose is 2.5 mg weekly for at least four weeks. It is the starter dose, not the long-duration obesity-trial floor. The first 72-week non-diabetic obesity dose is 5 mg weekly.¹ The lowest measured human trial dose is 1 mg weekly in type 2 diabetes.¹³
Is 2.5 mg tirzepatide therapeutic?
It depends on the claim. The label treats 2.5 mg as the starting dose before 5 mg. A short non-diabetic cohort measured a flat 2.5 mg dose for about four weeks and found weight and insulin-resistance movement.¹⁴ That makes "2.5 mg has no data" outdated. It still does not make 2.5 mg equivalent to the 5 mg long-duration obesity-trial floor.
How much weight will I lose on tirzepatide?
In the 72-week non-diabetic obesity trial, adults lost -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg.¹ Real-world outcomes vary because dose, adherence, baseline metabolic state, and access patterns vary. Formal RWE supports reported six-month outcomes on mixed lower-dose exposure, not pure microdose proof.¹²
Microdosing
What is a tirzepatide microdose?
A microdose is any weekly dose below the 2.5 mg label starter, usually 0.5-2 mg weekly. The 1 mg dose has direct human T2D trial activity.¹³ Below 1 mg is more speculative. The microdose case is best framed as metabolic or maintenance translation, not proven 72-week obesity dosing.
How do you microdose tirzepatide?
Pen-based Mounjaro and Zepbound products do not dose below 2.5 mg. Sub-2.5 mg dosing depends on product format, clinician supervision, and current compounding rules. When vial-based dosing is appropriate, most low-dose users start at 0.5 or 1 mg weekly, hold for at least four weeks, and adjust only if hunger, waist, labs, or tolerability call for it.
What are the benefits of microdosing tirzepatide?
The plausible benefits are quieter food noise, better insulin-sensitivity markers, and a lower side-effect burden than therapeutic-dose obesity treatment. The evidence is not equal across endpoints. The 1 mg dose has direct T2D glycemic data, 2.5 mg has short non-diabetic data, and 0.5-2 mg weight/body-composition claims remain extrapolated.¹³ ¹⁴
Does microdosing tirzepatide work for weight loss?
It can, but the evidence is weaker than the label-dose weight-loss evidence. No 72-week obesity trial tested below 5 mg. Modeled 1-2 mg outcomes should be treated as projections. At 2.5 mg, Barrea 2026 gives a short direct signal: -4.7% body weight over about four weeks.¹⁴
How much volume do I draw for a tirzepatide microdose?
Volume depends on concentration. A 10 mg vial mixed with 2 mL BAC water gives 5 mg/mL. A 1 mg dose draws 0.2 mL, or 20 units on a U-100 syringe. A 0.5 mg dose draws 0.1 mL, or 10 units. The calculator handles other vial sizes and BAC volumes.
Maintenance and step-down
What is the maintenance dose after weight loss?
The clearest practical band is 5-10 mg weekly. A 2.5 mg weekly track is plausible for stable maintainers who want less drug load, with short direct data and real-world support.¹² ¹⁴ The strongest settled maintenance evidence is that continuing tirzepatide works better than stopping.⁹ Step-down to 5 mg is being directly tested, but the local corpus treats that trial as design-level only.
Can you microdose tirzepatide for maintenance?
Yes, with careful framing. Step-down to 2.5 mg weekly has a short direct non-diabetic signal and real-world support. Below 2.5 mg is weaker evidence: it is extrapolated from the 1 mg T2D anchor, pharmacokinetics, and mechanism. The goal is stable weight, waist, hunger, strength, and labs, not continued rapid loss.
How do you microdose tirzepatide for maintenance?
Step down gradually after goal weight is stable: 15 -> 10 -> 7.5 -> 5 -> 2.5 mg, then only consider 2 or 1 mg if 2.5 mg feels heavier than needed. Hold each step for 8-12 weeks. If hunger, waist, weight, or strength drift, the lower dose is not carrying the maintenance load.
Can I keep tirzepatide at 2.5 mg instead of titrating up?
Sometimes. The label positions 2.5 mg as the starter dose before 5 mg, but short dose-isolated non-diabetic data show weight and insulin-resistance movement at 2.5 mg.¹⁴ That makes it a defensible low-dose floor for selected users, but it does not replace the 5 mg long-duration obesity-trial floor.
Is there a lower tirzepatide maintenance dose?
The lowest labeled dose is 2.5 mg weekly. Sub-2.5 mg maintenance is off-label, product-format dependent, and evidence-light. It can be reasonable as a cautious experiment for stable maintainers, but it should be judged by metrics: hunger, waist, weight, strength, glucose, and lipids.
Can I split-dose tirzepatide?
Yes, but it is a practice strategy rather than the trial schedule. The same weekly total can be divided into two injections, often every 3.5 days, to smooth peak and trough exposure. Weekly dosing remains the label and trial schedule.
Can I take tirzepatide every other week for maintenance?
Some maintainers try extended intervals, but this is an evidence-light strategy. The tirzepatide half-life is about 5 days, so a 10-14 day interval creates a real low-exposure period before the next injection. Hunger or waist drift in the back half of the interval is a sign that weekly dosing may be needed.
Can I take tirzepatide once a month?
Monthly tirzepatide is not a defensible maintenance schedule. With a roughly 5-day half-life, drug exposure is very low for most of the month. If the goal is lower drug load, weekly 2.5 mg or a cautious 10-14 day interval is more coherent than a monthly pulse.
Can I switch from tirzepatide to semaglutide for maintenance?
It can work for scale-weight maintenance, especially if access or cost drives the decision. The trade-off is body-composition logic: semaglutide does not carry tirzepatide's GIP-forward profile, and the non-diabetic DXA comparison favors tirzepatide.³ Switch decisions belong with a clinician, and the first weeks should be watched for hunger return, waist drift, and GI changes.
Body composition, liver, and safety
Does tirzepatide preserve lean mass better than semaglutide?
The best non-diabetic body-composition anchor favors tirzepatide: about 75:25 fat-to-lean loss in tirzepatide DXA data versus about 62:38 in semaglutide DXA data.³ This is cross-trial evidence, not a maintenance-dose head-to-head DXA result. Protein and resistance training still matter.
How much can tirzepatide reduce liver fat?
In a type 2 diabetes MRI substudy, tirzepatide produced large liver-fat reductions at therapeutic doses.⁶ In biopsy-confirmed MASH with fibrosis, 62% of participants on 15 mg had MASH resolution versus 10% on placebo.¹⁰ These are not microdose liver-fat data.
What are the most common side effects?
Gastrointestinal effects are the most common: nausea, diarrhea, constipation, vomiting, abdominal discomfort, and dyspepsia. They are dose-dependent and cluster during escalation. Tirzepatide also produces a modest dose-dependent resting heart-rate increase in trials, with larger short-term rises in some users during titration.¹ Oral contraceptive absorption can fall after initiation and dose escalation because gastric emptying slows; label guidance recommends non-oral or barrier contraception for 4 weeks after starting and 4 weeks after each increase.
Can you take metformin and tirzepatide together?
Yes, and many T2D trials added tirzepatide on top of metformin. The combination is common in diabetes care. For non-diabetic users, the question is whether both are needed: tirzepatide is much stronger for weight loss at 5 mg and above, while metformin is cheaper, oral, and more modest.
Stopping tirzepatide
What happens when you stop tirzepatide?
Stopping usually brings appetite and weight-regain pressure back. In the withdrawal trial, continuation preserved weight loss far better than placebo switch.⁹ A step-down plan is not the same as stopping, but it still needs monitoring: hunger, waist, scale trend, strength, and labs should stay stable before the next reduction.
Can you stop tirzepatide cold turkey?
There is no withdrawal syndrome, but cold-stopping raises regain risk. A taper from maintenance dose over 12-16 weeks gives time to lock in protein, resistance training, hunger tracking, and any metric-driven support before the drug signal fades.
Do you gain weight back after stopping tirzepatide?
Often, yes, without continued support. The withdrawal trial showed clear regain pressure after placebo switch.⁹ Tapering, protein, resistance training, and clinical follow-up can reduce risk, but no post-stop protocol guarantees maintenance.
How do you keep weight off after stopping tirzepatide?
Use three layers: taper instead of cold-stop, keep protein at roughly 1.6 g/kg or higher if tolerated, and train against strength loss. Track hunger, waist, weight, and strength before the scale moves too far. Optional support belongs to measured problems, not routine stacking.
Related Topics
- Tirzepatide Deep Dive — mechanism, clinical results, and comparison context
- GLP-1 Dosing Optimizer — split-frequency modeling and plasma curves
- GLP-1 Reconstitution Calculator — per-vial BAC water and syringe-unit charts for tirzepatide
- Full Reconstitution Calculator — all-peptide vial math and custom BAC volumes
- GLP-1 Lean Mass Guide — protein, training, and body-composition evidence
- Semaglutide vs Tirzepatide — direct comparison and evidence boundaries
References
¹ Tirzepatide for non-diabetic obesity — SURMOUNT-1, 72 weeks, treatment-regimen estimand: Jastreboff NEJM 2022.
² Tirzepatide vs semaglutide in non-diabetic obesity — direct head-to-head maximum-dose comparison: Aronne NEJM 2024.
³ Tirzepatide body-composition DXA substudy — pooled 5/10/15 mg SURMOUNT-1 substudy, about 75:25 fat-to-lean loss: Look DOM 2025.
⁴ Type 2 diabetes body-composition imaging — instrument-specific comparison against semaglutide; useful but not a clean non-diabetic maintenance proxy: Diabetes Res Clin Pract 2023.
⁵ Tirzepatide vs semaglutide in type 2 diabetes — SURPASS-2, 40 weeks: Frias NEJM 2021.
⁶ Tirzepatide MRI substudy in type 2 diabetes with fatty liver — liver fat, visceral fat, and muscle-quality imaging: Gastaldelli Lancet Diabetes Endocrinol.
⁷ Adipocyte GIP-receptor thermogenesis and tirzepatide pharmacokinetics — GIPR-driven futile calcium cycling from Yu et al.; PK half-life and steady-state timing from label and population PK data: Yu Cell Metab.
⁸ Tirzepatide receptor pharmacology — imbalanced dual agonism, with GIP-forward receptor activity and published receptor-engagement modeling: Coskun Mol Metab 2018; Willard JCI Insight 2020.
⁹ Tirzepatide maintenance after weight loss — SURMOUNT-4 continuation vs placebo switch; SURMOUNT-MAINTAIN is design-level evidence in the local corpus until results rows are present: Aronne JAMA 2024; NCT06047548.
¹⁰ Tirzepatide for MASH with fibrosis — 15 mg produced 62% MASH resolution vs 10% placebo: Loomba NEJM 2024.
¹¹ Tirzepatide for obstructive sleep apnea with obesity — AHI reduction at therapeutic dosing: Malhotra NEJM 2024.
¹² Real-world tirzepatide dosing patterns and outcomes — Mody Diabetes Therapy 2025; Hankosky Diabetes & Metabolism 2025; Hankosky Diabetes Obesity & Metabolism 2025; Le Roux Journal of Endocrinological Investigation 2026; Duncan Obesity Pillars 2026. Local corpus summary: >40,000 users, common sub-10 mg persistence, modal 5 mg patterns, 5 -> 2.5 mg de-escalation in a subset, and dose-heterogeneous six-month outcomes.
¹³ Phase 2 tirzepatide dose-ranging trial in type 2 diabetes — 1 mg, 5 mg, 10 mg, and 15 mg arms over 26 weeks: Frias Lancet 2018.
¹⁴ Dose-isolated 2.5 mg tirzepatide in non-diabetic obesity — 70-patient Italian outpatient cohort over about 4 weeks: body weight -4.7%, fasting insulin -25%, insulin-resistance score -30%; Barrea EXCLI Journal 2026 25:191-203.
Medical Disclaimer
The content in this calculator is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.
